(Corrects to fix typo in paragraph 4) (Reuters) -Life science real estate investment trust Alexandria Real Estate Equities reduced its full-year forecast for adjusted funds from operations (FFO) on ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Former government health officials fear the Trump administration is moving to slow-walk vaccine approvals, including by ...

Details for the poster presentation are as follows: Presentation Title: An mRNA-encoded masked IL-12 improves systemic tolerability while maintaining anti-tumor efficacy in preclinical studies Poster ...

Under President Trump, the Food and Drug Administration may no longer approve seasonal COVID-19 vaccines updated for the ...

US pharmaceutical giant Moderna is under serious scrutiny in the United Kingdom after allegations emerged that the company ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

The FDA has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a post-approval commitment ...

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...

The technology is genuinely useful for scientific discovery, but its applications are less dramatic than you might think.